David Jagielski is a writer for The Motley Fool and BAYSTREET.CA MEDIA CORP. His articles cover a wide range of investment topics, including stock analysis, market trends, and investment strategies. David's work has been featured in reputable publications such as USA TODAY, Yahoo Finance, and Nasdaq.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
David's extensive coverage in investment analysis and data citations suggests he is likely to respond well to pitches that provide unique insights into stock performance, investment strategies, and financial trends. He often delves into specific companies' financials and market performance, so a pitch offering exclusive insider perspectives or expert analysis on these topics may capture his attention.
Given David's consistent focus on the healthcare & pharmaceutical sector as part of his investment analysis, he may be particularly interested in pitches related to this industry such as emerging trends, key players’ performances, or significant regulatory changes impacting healthcare stocks.
It’s important for potential contributors reaching out to David Jagielski to ensure their content aligns with his focus on providing detailed investment analyses supported by relevant data.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: David Jagielski
Key Points Apple, Bank of America, and American Express are the top three holdings in Berkshire Hathaway's portfolio. These companies all have solid fundamentals and have been growing their businesses in recent years. Motley Fool Issues Rare “All In” Buy Alert
By: David Jagielski
Is Canopy Growth closer to entering the U.S. cannabis market?
There's a lot of excitement around Iovance Biotherapeutics (NASDAQ: IOVA) as its shares are up over 40% year-to-date.
A great way for investors to collect a safe dividend is to load up on top utility stocks. These companies generate recurring, consistent revenue, and often pay a lot in dividends. And an exchange-traded fund (ETF) can easily give investors exposure to ...
By: David Jagielski
Shares of Meta Platforms (NASDAQ:META) nosedived after earnings last week, falling to levels it hasn’t been at since early February. Revenue for the first three months of 2024 was up 27% to $36.5 billion. The ad business continues to look strong for ...
By: David Jagielski
Alphabet Declares First Dividend Payment Bad News Doesn't Make BCE a Bad Buy Johnson & Johnson Reports Profit Beat And Lifts Dividend By 4.2%
Key Points An EU study confirms there's no evidence linking Ozempic and Wegovy to an increase in suicidal thoughts. Side effects could be a key differentiator when it comes to which weight-loss and diabetes drugs succeed. Ozempic and Wegovy are Novo Nordisk's top sellers, and they generated impressive growth last year. 10 stocks we like better than Novo Nordisk
Key Points Americans now believe they'll need around $1.5 million by retirement to live comfortably. Those financial needs will vary from person to person, depending on someone's individual lifestyle. Investing in growth-oriented funds can put investors in much stronger financial positions by the time they retire. 10 stocks we like better than VanEck ETF Trust - VanEck Semiconductor ETF
Key Points Dividend increases can usually be a sign of financial health -- but not always. In some cases, companies raise their payouts simply for the sake of extending a streak. Johnson & Johnson, Southern, and TJX Companies all recently announced dividend hikes. 10 stocks we like better than Johnson & Johnson
Is this rising healthcare stock a good buy right now?
(833) 317-6278 
